造血干细胞移植后CIK细胞生物治疗的临床观察  

Clinical observation of CIK cells biological therapy after haemopoietic stem cells transplantation

作　　者：曾瀚庆[1] 罗云[1] 张萍[1] 娄世锋[1] 梁顺嗣[1] 邓建川[1] 陈林[1] 陈姝[1] 周慷[1] 张颖[1] 

机构地区：[1]重庆医科大学附属第二医院血液内科,重庆400010

出　　处：《现代医药卫生》2014年第11期1639-1640,1643,共3页Journal of Modern Medicine & Health

摘　　要：目的：观察细胞因子诱导的杀伤细胞（CIK细胞）对造血干细胞移植后血液肿瘤患者维持治疗的疗效。方法2005年9月至2010年6月收治血液恶性肿瘤患者12例，其中行自体造血干细胞移植8例，异基因造血干细胞移植4例；移植造血重建后1~3个月内，利用血细胞分离机分离患者（自体移植）及供者（异体移植）的外周血单个核细胞，在体外用多种细胞因子[抗CD3单克隆抗体（OKT3）、白介素-2（IL-2）、干扰素-γ（IFN-γ）等）]共同培养后获得CIK细胞，分次回输给患者。随访观察患者接受治疗后血常规及骨髓等指标的变化及不良反应，同时记录患者的生存期。结果8例自体干细胞移植患者有2例复发，其中1例17个月后死亡，其余6例长期生存；4例异体干细胞移植患者有1例复发，5个月后死亡，其余3例长期生存；4例患者静脉滴注CIK细胞时出现畏寒、寒战、发热，经对症处理均缓解，其余未见不良反应。结论造血干细胞移植后CIK细胞生物治疗延长了患者的生存期，改善了患者的生活状况，未见明显不良反应。Objective To investigate the effects of the maintenance treatment of adoptive immunotherapy of cytokine in-duced killer（CIK） cells for the patients with malignant hematopathy previously given haemopoietic stem cell transplantation （HSCT）. Methods Among the 12 patients with malignant hematopathy ,who were received from September 2005 to June 2010 ,8 patients were treated with auto-hematopoietic stem cell transplantation （auto-HSCT） and 4 with allo-hematopoietic stem cell transplanta-tion （allo-HSCT）. It was used the blood cell separator to separate the peripheral blood mononuclear cells of the patients （auto transplantation） and the suppliers（allotransplantation） within 1-3 months after rebuilding of transplantation and blooding. The CIK cells were obtained after cultivating with various cells such as OKT3,IL-2,IFN-γtogether in vitro and retransformed to the patients in times. Follow-up observed the indicators of blood routine examination and bone marrow as well as adverse reaction ,and recorded the patients′lifetime. Results 2 cases relapsed among 8 patients with auto-HSCT including 1 died 17 months after the treatment,and the other 6 cases had long-term survival;1 case recurred among 4 patients with allo-HSCT,and died after 5 months,the other 3 cases had long-term survival. In the process of CIK for intravenous injection,4 cases had chills,shiver,fever, and got alleviated after symptomatic treatment ,there were no adverse reaction on the others. Conclusion CIK biological therapy after haemopoietic stem cells transplantation extended the survival time of the patients ,improved their life condition without obvi-ous adverse reaction.

关 键 词：造血干细胞移植 移植 自体 杀伤细胞 细胞因子类 干细胞移植 基因 免疫疗法 过继 血液肿瘤 

分 类 号：R733[医药卫生—肿瘤]